S Plotkin

Summary

Affiliation: Sanofi Pasteur

Publications

  1. ncbi request reprint The global pertussis initiative: process overview
    Stanley Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:S7-9. 2005
  2. ncbi request reprint Vaccines: past, present and future
    Stanley A Plotkin
    Sanofi Pasteur and the University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18901, USA
    Nat Med 11:S5-11. 2005
  3. ncbi request reprint Why certain vaccines have been delayed or not developed at all
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:631-4. 2005
  4. ncbi request reprint New rotavirus vaccines
    Stanley A Plotkin
    Sanofi Pasteur and the Department of Pediatrics, University of Pennsylvania, Doylestown, 18901, USA
    Pediatr Infect Dis J 25:575-6. 2006
  5. ncbi request reprint Aims, scope and findings of the global pertussis initiative
    Stanley Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:S5-6. 2005
  6. ncbi request reprint The history of rubella and rubella vaccination leading to elimination
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
    Clin Infect Dis 43:S164-8. 2006
  7. ncbi request reprint [Tropical vaccinology at the dawn of the 21st century]
    S Plotkin
    L Université de Pennsylvanie, Philadelphie, USA
    Med Trop (Mars) 67:320. 2007
  8. doi request reprint Vaccines: correlates of vaccine-induced immunity
    Stanley A Plotkin
    Sanofi Pasteur, Doylestown, Pennsylvania, USA
    Clin Infect Dis 47:401-9. 2008
  9. pmc Sang Froid in a time of trouble: is a vaccine against HIV possible?
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    J Int AIDS Soc 12:2. 2009
  10. pmc Vaccines: the fourth century
    Stanley A Plotkin
    University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18902, USA
    Clin Vaccine Immunol 16:1709-19. 2009

Collaborators

Detail Information

Publications29

  1. ncbi request reprint The global pertussis initiative: process overview
    Stanley Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:S7-9. 2005
    ..This article describes the processes undertaken to conduct the Initiative...
  2. ncbi request reprint Vaccines: past, present and future
    Stanley A Plotkin
    Sanofi Pasteur and the University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18901, USA
    Nat Med 11:S5-11. 2005
    ..With all this come new problems in the production, regulation and distribution of vaccines...
  3. ncbi request reprint Why certain vaccines have been delayed or not developed at all
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Health Aff (Millwood) 24:631-4. 2005
    ..However, to take things further, there must be a vaccine manufacturer, a regulatory authority ready to give permission for the use of the vaccine, and public health authorities that will recommend and foster vaccination...
  4. ncbi request reprint New rotavirus vaccines
    Stanley A Plotkin
    Sanofi Pasteur and the Department of Pediatrics, University of Pennsylvania, Doylestown, 18901, USA
    Pediatr Infect Dis J 25:575-6. 2006
  5. ncbi request reprint Aims, scope and findings of the global pertussis initiative
    Stanley Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:S5-6. 2005
  6. ncbi request reprint The history of rubella and rubella vaccination leading to elimination
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA
    Clin Infect Dis 43:S164-8. 2006
    ..The present article summarizes the clinical syndrome of CRS, the process by which the vaccine was developed, and the history leading up to elimination, as well as the possible extension of elimination on a wider scale...
  7. ncbi request reprint [Tropical vaccinology at the dawn of the 21st century]
    S Plotkin
    L Université de Pennsylvanie, Philadelphie, USA
    Med Trop (Mars) 67:320. 2007
  8. doi request reprint Vaccines: correlates of vaccine-induced immunity
    Stanley A Plotkin
    Sanofi Pasteur, Doylestown, Pennsylvania, USA
    Clin Infect Dis 47:401-9. 2008
    ..In situations where the true correlate of protection is unknown or difficult to measure, surrogate tests (usually antibody measurements) must suffice as predictors of protection by vaccines. Examples of each circumstance are given...
  9. pmc Sang Froid in a time of trouble: is a vaccine against HIV possible?
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    J Int AIDS Soc 12:2. 2009
    ..But HIV is not the only vaccine to experience difficulties; what lessons can we glean from prior vaccine development?..
  10. pmc Vaccines: the fourth century
    Stanley A Plotkin
    University of Pennsylvania, 4650 Wismer Road, Doylestown, Pennsylvania 18902, USA
    Clin Vaccine Immunol 16:1709-19. 2009
    ..However, the multiplicity of strategies now available, discussed in this article, portends even more successful development of vaccines...
  11. ncbi request reprint Mumps vaccine virus strains and aseptic meningitis
    Marie Claude Bonnet
    Sanofi Pasteur, Medical Affairs International, 2, avenue Pont Pasteur, 69007 Lyon, France
    Vaccine 24:7037-45. 2006
    ....
  12. ncbi request reprint [New vaccination strategies]
    Stanley A Plotkin
    Sanofi Pasteur, 4650 Wismer Road, Doylestown, PA 18902, USA
    Bull Acad Natl Med 192:511-8; discussion 518-9. 2008
    ..Also, new methods of vaccine delivery besides injection will be used and new adjuvants will be added to vaccines in order to stimulate specific responses. The future of vaccination is promising...
  13. ncbi request reprint Six revolutions in vaccinology
    Stanley A Plotkin
    University of Pennsylvania, Philadelphia, PA, USA
    Pediatr Infect Dis J 24:1-9. 2005
    ..I propose new delivery systems as the most likely to succeed, although humbly admitting that prediction is always subject to error...
  14. pmc Correlates of protection induced by vaccination
    Stanley A Plotkin
    Vaxconsult, 4650 Wismer Road, Doylestown, PA 18902, USA
    Clin Vaccine Immunol 17:1055-65. 2010
    ..Cellular immunity acts to kill or suppress intracellular pathogens and may also synergize with antibody. For some vaccines, we have no true correlates, but only useful surrogates, for an unknown protective response...
  15. ncbi request reprint Commentary: congenital rubella syndrome should not be a disease of poor countries
    Stanley A Plotkin
    University of Pennsylvania and Aventis Pasteur, Doylestown, PA 18901, USA
    Pediatr Infect Dis J 23:1123-4. 2004
  16. ncbi request reprint Vaccines, vaccination, and vaccinology
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, and Aventis Pasteur, Doylestown, Pennsylvania, USA
    J Infect Dis 187:1349-59. 2003
  17. doi request reprint Use of predictive markers of HIV disease progression in vaccine trials
    S Gurunathan
    Sanofi Pasteur, R and D, Swiftwater, PA 18370 0187, USA
    Vaccine 27:1997-2015. 2009
    ..The review also provides perspectives on magnitude of viral load reduction, durability of viral load reduction for reduced progression of HIV disease...
  18. ncbi request reprint A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects
    K Berencsi
    Wistar Institute, Philadelphia, PA, USA
    J Infect Dis 183:1171-9. 2001
    ..Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV...
  19. ncbi request reprint Of vaccination and infectious diseases in 2003
    Stanley A Plotkin
    University of Pennsylvania, USA
    Adv Exp Med Biol 549:1-4. 2004
  20. ncbi request reprint Vaccines in the 21st century
    Stanley A Plotkin
    Department of Pediatrics, University of Pennsylvania, Philadelphia, USA
    Hybrid Hybridomics 21:135-45. 2002
  21. ncbi request reprint The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants
    H Fred Clark
    Division of Infectious Diseases, ARC 1202, Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Pediatr Infect Dis J 25:577-83. 2006
    ..In developing countries, it is associated with a high mortality. A licensed vaccine against rotavirus was withdrawn because of a causal association with intussusception. A new vaccine has been developed and is a candidate for licensure...
  22. doi request reprint Varicella vaccination in Japan, South Korea, and Europe
    Catherine Sadzot-Delvaux
    Unit of Fundamental Virology and Immunology, Department of Life Sciences, University of Liege, Sart Tilman, Belgium
    J Infect Dis 197:S185-90. 2008
    ..The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents...
  23. ncbi request reprint An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960
    Stanley A Plotkin
    Am J Med 112:4-12; discussion 2-3. 2002
  24. ncbi request reprint Microbial evolution: antitoxin vaccines and pathogen virulence
    Benoit Soubeyrand
    Department of Medical Affairs, Aventis Pasteur, 69007 Lyon, France
    Nature 417:609-10; discussion 610. 2002
    ..The model proposed by Gandon et al. may therefore be an oversimplification, with the outcome depending on the biological details of both the pathogen and the vaccine...
  25. ncbi request reprint The cost of not implementing routine neonates immunization programmes in HBsAg high prevalence countries
    Pierre Chauvin
    Vaccine 20:2848-50. 2002
  26. ncbi request reprint Chimpanzees and journalists
    Stanley A Plotkin
    Vaccine 22:1829-30. 2004
  27. ncbi request reprint The late sequelae of Arrowsmith
    Stanley A Plotkin
    Medical and Scientific Advisor, Aventis Pasteur, Swiftwater, PA 18370, USA
    Pediatr Infect Dis J 21:807-9. 2002
  28. ncbi request reprint Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules
    Isabelle Parent Du Chatelet
    Association pour l Aide a la Medecine Preventive, 25 rue du Dr Roux, 75724 Cedex 15, Paris, France
    Vaccine 21:1710-8. 2003
    ..Combined schedules of OPV and IPV in the form of diphtheria-pertussis-tetanus-IPV vaccine (DPT-IPV) may be useful to accelerate eradication of polio in developing countries...
  29. ncbi request reprint Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations
    Emmanuel Vidor
    Sanofi Pasteur, Campus Merieux, Marcy l Etoile, France
    Hum Vaccin 4:328-40. 2008
    ..The consistent immunogenicity of the DTaP(2Fr) vaccine is accompanied by effectiveness in controlling pertussis disease in the areas where it is used on a large scale with good vaccination coverage...